AqueSys, Inc., an Aliso Viejo, CA-based medical device company focused on technology for treating glaucoma, secured $43.6m in Series D financing.
The round was led by a new undisclosed investor with participation from existing investors Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures, and SV Life Sciences.
Led by Ron Bache, President and CEO, AqueSys focuses on the development, manufacturing, and commercialization of the XEN Gel Stent technology used to treat patients with the sight-threatening disease, glaucoma.
The company successfully completed enrollment of their first FDA IDE study, and has begun enrollment of their second FDA approved IDE study utilizing an additional XEN Gel Stent model. Furthermore, it recently initiated focused international commercialization.